Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

NCT01495221 is registered in ClinicalTrials.gov with Vitreous -Retina- Macula Consultants of New York as lead sponsor.

NCT NCT01495221
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01495221 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2011
Completion date
March 31, 2013
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amd (with persistent or recurrent fluid despite monthly intravitreal anti-vegf therapy)